Side-by-side · Research reference

GHRP-6vsOxytocin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED10/36 cited

BFDA-ApprovedHUMAN-REVIEWED11/51 cited

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Oxytocin

Neuropeptide Hormone · FDA-Approved

24–48 IUIntranasal dose (research)Prinsen 2026 Burmester 2025

~3–20 minPlasma half-life

9 AAPeptide length

Intranasal · IV (obstetric)

01Mechanism of Action

Parameter

GHRP-6

Oxytocin

Primary target

Ghrelin receptor (GHS-R1a)Bowers 1990

Oxytocin receptors (OXTR) — hypothalamus, amygdala, hippocampus, ventral tegmental area

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

OXTR activation → Gq/11-coupled signaling → modulation of GABAergic, dopaminergic, serotonergic pathways → enhanced synaptic plasticity, neurogenesis, emotional regulation

Downstream effect

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Social bonding enhancement, trust behavior, gaze modulation, reciprocal eye contact, anti-inflammatory and antioxidant neuroprotection, reduced amygdala threat responsePaul 2026 Prinsen 2026 Yuan 2026

Feedback intact?

—

Yes — endogenous oxytocin-mediated feedback via central and peripheral OXTR pathways

Origin

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Endogenous 9-amino-acid peptide synthesized in hypothalamic paraventricular and supraoptic nuclei, released from posterior pituitaryPaul 2026

Antibody development

—

02Dosage Protocols

Parameter

GHRP-6

Oxytocin

Standard dose

100–200 mcg per injectionBowers 1990

—

Frequency

1–3× per day

—

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceBowers 1990

—

Duration

8–12 weeks on / 4 off

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-meal preferred for appetite support

—

Half-life

~15 minMalagón 1999

~3–20 min (plasma); CNS effects persist longer

Intranasal (research — autism, social cognition)

—

24–48 IUPrinsen 2026 Burmester 2025

Single dose; chronic dosing protocols vary (4–12 weeks documented).

Frequency (research)

—

Once daily to twice daily

IV (obstetric — labor induction)

—

0.5–2 mU/min, titrated every 30–60 min

FDA-approved Pitocin protocol; maximum 20–40 mU/min per institutional guidelines.

Evidence basis (social cognition)

—

Phase 1–2 RCTs in ASD, schizophrenia, social anxiety

Evidence basis (obstetric)

—

FDA-approved · standard-of-care

Duration (research protocols)

—

4–12 weeks chronic administrationPrinsen 2026

Timing (intranasal)

—

Morning or pre-social interaction

Acute effects within 30–90 minutes.

04Side Effects & Safety

Parameter

GHRP-6

Oxytocin

Hunger

Pronounced — defining feature vs ipamorelin

—

Cortisol elevation

Mild

—

Prolactin elevation

Mild

—

Injection site reaction

Mild

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Nasal irritation (intranasal)

—

Mild dryness, congestion

Headache

—

Occasional, transient

Uterine hyperstimulation (IV obstetric)

—

Tachysystole, fetal distress — requires continuous monitoring

Negative interpretation bias (adolescents)

—

Increased negative interpretations of ambiguous social scenarios in female adolescents (with and without eating disorders)Burmester 2025

Hyponatremia (IV)

—

Water intoxication risk with prolonged high-dose IV infusion

Hypersensitivity

—

Rare allergic reactions

Individual variability

—

Salivary oxytocin levels show high subgroup variability in ASD populations; no consistent group-level differences vs controls in some studiesYılmazer 2025

Absolute Contraindications

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Oxytocin

·Fetal distress or abnormal fetal heart rate patterns (obstetric)
·Cephalopelvic disproportion
·Hypersensitivity to oxytocin

Relative Contraindications

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

Oxytocin

·Severe cardiovascular disease (obstetric use)
·Hypertonic or hyperactive uterus
·Prior uterine surgery or cesarean section (relative — use cautiously)

05Administration Protocol

Parameter

GHRP-6

Oxytocin

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Administer 24–48 IU (typically 3–6 puffs per nostril) using nasal spray device. Patient should be seated, head tilted slightly forward. Avoid sniffing deeply; allow passive absorption.

2. Injection site

SQ — abdomen. Rotate sites.

Administer 30–90 minutes before anticipated social interaction or cognitive assessment. Acute effects peak within 30–60 minutes.

3. Timing

Pre-meal for appetite support; pre-sleep for GH alignment.

Dilute oxytocin 10 units in 1000 mL isotonic saline. Initiate at 0.5–2 mU/min via infusion pump. Titrate every 30–60 minutes based on contraction pattern and fetal heart rate. Continuous electronic fetal monitoring required.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Store at 2–8 °C (refrigerated). Do not freeze. Protect from light. Discard if solution is discolored or contains precipitate.

5. Needle

29–31G, 4–8 mm insulin syringe.

Chronic administration protocols (4–12 weeks) documented in pediatric ASD populations. Daily or twice-daily intranasal administration. Safety profile in chronic use still under investigation.